Illustration: Sarah Grillo/Axios
Clinical-stage obesity biopharma company Kailera Therapeutics raised $625 million, pricing its IPO at $16 per share — the top of its targeted range.
The big picture: It's one of a handful of biotech companies headed to the public markets this spring as the sector's stocks soar.
